7-氟-1H-吲唑-3-胺 | 404827-60-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 7-氟-1H-吲唑-3-胺
• 英文名称: 7-fluoro-1H-indazol-3-amine
• CAS: 404827-60-7
• 化学式: C₇H₆FN₃
• mdl: MFCD03426694
• 分子量: 151.143
• InChiKey: GQKRISMLLXVZKY-UHFFFAOYSA-N

物化性质

• 沸点：
  379.3±22.0 °C(Predicted)
• 密度：
  1.487±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Fluoro-1H-indazol-3-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Fluoro-1H-indazol-3-amine
CAS number: 404827-60-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6FN3
Molecular weight: 151.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-氟-1H-吲唑-3-胺 在 三氟化硼乙醚 、 亚硝酸异戊酯 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 7-氟-3-碘-1H-吲唑
  参考文献：
  名称：

  [EN] FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF
  [FR] COMPOSÉS INDAZOLE SUBSTITUÉS PAR FLUOR ET LEURS UTILISATIONS

  摘要：

  氟取代吲唑化合物，含有这些化合物的药物组合物及其用途。这些化合物和药物组合物可用作可溶性鸟苷酸环化鸟苷酸酶模拟剂。

  公开号：

  WO2018188590A1
• 作为产物：
  描述：

  2,3-二氟苯腈 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以91%的产率得到7-氟-1H-吲唑-3-胺
  参考文献：
  名称：

  (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

  摘要：

  本申请涉及新型取代的(氮杂)吡啶吡唑吡嘧啶酮和吲唑吡嘧啶酮，以及它们的制备方法，这些化合物可单独或组合使用于治疗和/或预防疾病的方法中，特别是用于治疗和/或预防患有或不患有基础遗传或获得性出血性疾病的患者的急性和复发性出血，其中出血与来自月经过多、产后出血、出血性休克、创伤、手术、移植、中风、肝病、遗传性血管性水肿、鼻血和血液性关节积血后的滑膜炎和软骨损伤等疾病或医疗干预有关。

  公开号：

  US20150126449A1

文献信息

• Controllable Site-Selective Construction of 2- and 4-Substituted Pyrimido[1,2-<i>b</i>]indazole from 3-Aminoindazoles and Ynals
  作者：Xiang Liu、Jinlei Zhou、Jiatong Lin、Zemin Zhang、Suying Wu、Qiuxing He、Hua Cao

  DOI：10.1021/acs.joc.1c01094

  日期：2021.7.2

  straightforward and novel controllable site-selective construction of 2- and 4-substituted pyrimido[1,2-b]indazole from 3-aminoindazoles and ynals has been developed. The high regioselectivity of this reaction could be easily switched by converting different catalytic systems. In this way, a series of 2- and 4-substituted pyrimido[1,2-b]indazole derivatives were obtained in moderate to good yields. In addition, the

  已经开发出一种由 3-氨基吲唑和 ynals 直接且新颖的可控位点选择性构建 2-和 4-取代的嘧啶并[1,2 -b ]吲唑的方法。该反应的高区域选择性可以通过转换不同的催化体系轻松切换。通过这种方式，以中等至良好的收率获得了一系列2-和4-取代的嘧啶并[1,2- b ]吲唑衍生物。此外，还讨论了本方法制备的化合物3a的光物理性质。
• 2-吡啶取代脲结构小分子化合物及其合成和应用
  申请人：中国科学院上海药物研究所

  公开号：CN110818683B

  公开（公告）日：2023-04-14

  本发明涉及2‑吡啶取代脲结构小分子化合物及其合成和应用。具体地，本发明公开了式(I)所述的化合物，其对映异构体、非对映异构体、外消旋体或其混合物，或其药学上可接受的盐、水合物及溶剂合物及其制备方法和在制备ASK1小分子抑制剂，或预防和/或治疗与ASK1相关疾病，尤其是肝脏疾病、肺部疾病、心血管疾病、肾脏疾病和代谢性疾病的药物中的用途。
• [EN] INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] INDAZOLYL-PYRIMIDINES UTILISÉS EN TANT QU'INHIBITEURS DE KINASE
  申请人：GLAXO GROUP LTD

  公开号：WO2011120025A1

  公开（公告）日：2011-09-29

  Disclosed are compounds having the formula: or a salt thereof, wherein A, n, R1, R1A, and R2 are as defined herein, and methods of making and using the same.

  揭示了具有以下公式的化合物：或其盐，其中A、n、R1、R1A和R2如本文所定义，并且揭示了制备和使用这些化合物的方法。
• Synthesis of diverse nitrogen fused polycyclic dihydroisoquinoline (DHIQ) derivatives via GBB-based cyclic iminium induced double-annulation cascade
  作者：Sandip Gangadhar Balwe、Sandip S. Vagh、Yeon Tae Jeong

  DOI：10.1016/j.tetlet.2020.152101

  日期：2020.7

  for the synthesis of novel dihydroindazolo[3′,2′:2,3]imidazo[5,1-a]isoquinolinamines has been achieved through the three-component Groebke–Blackburn–Bienayme reaction. The transformation is based on sequential cascade processes involving imine formation followed by an intramolecular nucleophilic substitution to generate a highly reactive cyclic iminium species, which would undergo a rapid [4 + 1] formal

  通过合成实现了一种高效且独特的布朗斯台德酸介导的空前的环状亚胺诱导的双环级联反应（DAC）方案，用于合成新型二氢吲哚并[3'，2'：2,3]咪唑并[5,1- a ]异喹啉胺三组分Groebke–Blackburn–Bienayme反应。该转化基于顺序的级联过程，该过程涉及形成亚胺，然后进行分子内亲核取代，以生成高反应性的环亚胺，这些亚胺将以一锅方式快速[4 +1]正式的环加成步骤。通过采用容易获得的底物和简单的方法，该策略提供了新颖的骨架多样的复杂的氮稠合多环DHIQ衍生物，这将使该方法在有机合成中潜在有用。
• [EN] (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS<br/>[FR] (AZA)PYRIDOPYRAZOLOPYRIMIDINONES ET INDAZOLOPYRIMIDINONES UTILISÉES COMME INHIBITEURS DE LA FIBRINOLYSE
  申请人：BAYER PHARMA AG

  公开号：WO2015067549A1

  公开（公告）日：2015-05-14

  The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

  本申请涉及新型取代的(氮杂)吡啶吡唑吡嘧啶酮和吲唑吡嘧啶酮，以及它们的制备方法，这些化合物可单独或组合使用于治疗和/或预防疾病的方法中，特别是用于治疗和/或预防患有或不患有基础遗传或获得性出血性疾病的患者的急性和复发性出血，其中出血与来自以下组中选择的疾病或医疗干预相关，该组包括月经过多、产后出血、出血性休克、创伤、手术、移植、中风、肝病、遗传性血管性水肿、鼻血、以及血液积聚后的滑膜炎和软骨损伤。